StrainX Bioworks, a synthetic biology startup based in India, has successfully raised $13 million in a funding round led by Prime Venture Partners and Leo Capital, marking its first institutional investment after operating on bootstrap capital. This funding will enable StrainX to expand its research and development capabilities, enhance fermentation infrastructure, and grow its engineering and scientific teams. The company, founded by IIT Delhi alumni Akshay Mittal and Dr. Alok Malviya, focuses on precision fermentation, engineering microorganisms to produce essential molecules and proteins in controlled environments. With a demonstrated fermentation capacity of 10,000 litres, StrainX aims to scale production for commercialization both in India and international markets, including the US. Investors are optimistic about the startup's potential, citing its unique blend of scientific expertise and business acumen as key differentiators in the burgeoning field of synthetic biology.